Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT@home: Digital Support for Severe Asthma
NCT05831566Phase 3Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Jan 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide and formoterol in asthma (2 arms), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Difference in percentage of patients treated with biologicals after 6 months of follow up. Started Jan 2023; status: recruiting.
02
Drugs
budesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05831566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831566.